Luckbox Leans in with Mark Cuban
By James Melton
Cost Plus Drugs Company is selling prescription medications at dramatically low prices

What would happen if drug pricing made sense to consumers?
Mark Cuban Cost Plus Drug Company, which launched its online pharmacy about a year ago, is trying to answer that question. Its approach is easy to understand—even if it’s difficult to implement.
First, CPD negotiates directly with manufacturers to get the best possible price. It adds a 15% markup based on the per-pill price that CPD pays to buy the medicines. Then, CPD adds a flat $3 pharmacy labor fee and $5 standard shipping to get to the total retail price.
Cuban believes strongly in CPD’s mission and business model. Among his many ventures, this is the first company to...
Topics
-
AI arrives as a 9-year-old child
|Luckbox has been around only four years, but the editorial team and contributors draw upon decades of trading, financial and editorial experience to report on emerging investment and cultural trends.… -
Three AI Stocks to Watch
|As heavyweights Google and Microsoft duke it out over AI, upstarts like C3.ai enjoy natural advantages Don’t always go with the big names. When it comes to investing in artificial… -
If AI doesn’t take your job, it’ll change it. A lot.
By James Melton
|The new reality will favor those able and willing to collaborate effectively with AI AI is here. How soon it transforms the economy depends on how fast the technology advances.… -
AI & The Next Economy
|Artificial intelligence can spawn efficiency that will bring down wages and prices, but expect a bumpy ride Artificial intelligence is boosting the global economy’s efficiency, profitability and productivity, but it’s… -
AI Arrives
By Luckbox
|Artificial intelligence seems certain to steal millions of jobs in the coming months and could one day dominate the humans that created it. That’s a lot to contemplate, but we’re… -
When AI Eclipses Humanity
By Ed McKinley
|The singularity— the time when super intelligent computers surpass human understanding and shed human control—may soon be upon us Suppose a medical research team asks a chatbot to develop a… -
AI Imitates Art
|From painting to rap music, artificial intelligence is invading the art world. Creatives are coping with the fallout. Singer-songwriter Nick Cave didn’t like what he was hearing. “This song is… -
The AI Roundtable
By James Melton
|Four experts weigh in on the state of generative AI and the impact of ChatGPT. Just to be fair, we also asked the chatbot for its opinions. Luckbox: On a… -
AI’s Path To The Singularity
By Luckbox
|Duplicating human intelligence in a machine has proceeded in fits and starts over the last 70 or so years. But suddenly it’s gaining momentum at a dizzying pace, and the… -
Silicon Valley Bank: Backstop or Bailout?
|The U.S. government shuttered Signature Bank of New York and announced uninsured deposits from both Silicon Valley Bank and Signature Bank would be fully backstopped and accessible by March 13.… -
Key Inflation Report Looms After Powell Doubles Down on Future Rate Hikes
|Federal Reserve chairperson Jerome Powell appeared before Congress on March 6 and indicated that rates may have to increase more than expected in 2023 to tame persistently high inflation -
New 200% Aluminum Tariff Designed to Punish Russia
|Trading volumes surged in the aluminum futures market after the U.S. unveiled fresh tariffs on Russian aluminum exports -
What You Need to Know About Trading ‘Zero-day’ Options
|Options with zero days until expiration only exist for a single trading session, and recent market data suggests that trading volume in these Zero-day, or 0DTE, contracts has been surging… -
The Myth of Drug Expiration Dates
By Nav Dhillon
|There’s not necessarily anything scientific or magical about the dates printed on medications Those expiration dates stamped on everything from a gallon of milk to a bottle of acetaminophen don’t… -
ADHD Meds? You May Have to Wait
By James Melton
|A shortage began with Adderall and spread to Ritalin. A government crackdown made it worse. As 2023 began, the national Adderall shortage had spread to other drugs used to treat… -
Betting on Biotech
|Active investors can navigate the boom or bust biotech sector with the help of strategies like C-suite buying, cash to value and cash flow Sick people need medicine no matter… -
The First $100 Billion Drug
By Ed McKinley
|An obesity medication is reportedly poised to shatter the record for pharmaceutical sales volume A prescription drug that combats obesity is expected to become the biggest-grossing pharmaceutical in history, ringing… -
Off-label, But Lucrative
By Nav Dhillon
|Big pharma profits when doctors prescribe a drug for a disorder other than the one that earned FDA approval. The practice ranges from evidence-based to highly egregious. One in five… -
Competition Coming for AbbVie’s Blockbuster
|It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats Worldwide sales of Humira have totaled $200 billion in the last 20 years—just about the biggest haul… -
The Luckbox Roundtable
By James Melton
|Mark Cuban, the nation’s newest retail drug impresario, joins our expert panel to weigh in on the state of American pharma. Here’s what our panelists say lies ahead. (Luckbox lightly…